NEUROCRINE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEUROCRINE, and when can generic versions of NEUROCRINE drugs launch?
NEUROCRINE has two approved drugs.
There are twenty-two US patents protecting NEUROCRINE drugs.
There are one hundred and ninety-one patent family members on NEUROCRINE drugs in thirty-three countries.
Summary for NEUROCRINE
| International Patents: | 191 |
| US Patents: | 22 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for NEUROCRINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | 10,906,903 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | 11,311,532 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | 10,919,892 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
